Intellia Therapeutics, Inc.
NTLANASDAQHealthcare● Active
$13.58
+$0.04(+0.26%)
Market Cap$1.5B
P/E Ratio—
52W High$28.25
52W Low$7.31
Intellia Therapeutics, Inc. (NTLA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NTLA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.81
Est. -$0.92 · +12.0%
Revenue
$0.02B
Est. $0.01B · +9.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
NTLA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.80 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.92 | -$0.81 | +12.0% | $0.02B | $0.01B | +9.0% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.99 | -$0.83 | +16.2% | $0.02B | $0.01B | +92.1% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$1.02 | -$0.92 | +9.8% | $0.01B | $0.01B | +13.2% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.03 | -$0.99 | +3.9% | $0.01B | $0.01B | +1.3% |
| ▲ Q2 FY2025 | May 8, 2025 | -$1.26 | -$1.10 | +12.7% | $0.02B | $0.01B | +39.3% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$1.32 | -$1.24 | +6.1% | $0.01B | $0.01B | +18.5% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$1.37 | -$1.34 | +2.2% | $0.01B | $0.01B | +2.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.80
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.81
EPS Est.
-$0.92
EPS Surpr.
+12.0%
Revenue
$0.02B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.83
EPS Est.
-$0.99
EPS Surpr.
+16.2%
Revenue
$0.02B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.92
EPS Est.
-$1.02
EPS Surpr.
+9.8%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.99
EPS Est.
-$1.03
EPS Surpr.
+3.9%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$1.10
EPS Est.
-$1.26
EPS Surpr.
+12.7%
Revenue
$0.02B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$1.24
EPS Est.
-$1.32
EPS Surpr.
+6.1%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$1.34
EPS Est.
-$1.37
EPS Surpr.
+2.2%
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-0.53 | $-0.50 | $-0.41 | 4 |
| Q3 FY2029 | $-0.53 | $-0.50 | $-0.41 | 4 |
| Q2 FY2029 | $-0.53 | $-0.50 | $-0.41 | 7 |
| Q1 FY2029 | $-0.58 | $-0.55 | $-0.46 | 5 |
| Q4 FY2028 | $-0.36 | $-0.34 | $-0.28 | 5 |
| Q3 FY2028 | $-0.50 | $-0.47 | $-0.39 | 10 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 5 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 5 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +12.0% | $14.09 | $14.42 | +2.34% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +16.2% | $13.42 | $14.28 | +6.41% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +9.8% | $13.57 | $12.32 | -9.21% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +3.9% | $11.37 | $11.46 | +0.79% |
| ▲ Q2 FY2025 | May 8, 2025 | +12.7% | $7.29 | $8.28 | +13.58% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +6.1% | $10.80 | $10.86 | +0.56% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +2.2% | $16.06 | $16.00 | -0.37% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -8.3% | $21.31 | $22.38 | +5.02% |
Q2 FY2026+2.34%
Report Date
May 11, 2026
EPS Beat/Miss
+12.0%
Price Before
$14.09
Price After
$14.42
Q1 FY2026+6.41%
Report Date
Feb 26, 2026
EPS Beat/Miss
+16.2%
Price Before
$13.42
Price After
$14.28
Q4 FY2025-9.21%
Report Date
Nov 6, 2025
EPS Beat/Miss
+9.8%
Price Before
$13.57
Price After
$12.32
Q3 FY2025+0.79%
Report Date
Aug 7, 2025
EPS Beat/Miss
+3.9%
Price Before
$11.37
Price After
$11.46
Q2 FY2025+13.58%
Report Date
May 8, 2025
EPS Beat/Miss
+12.7%
Price Before
$7.29
Price After
$8.28
Q1 FY2025+0.56%
Report Date
Feb 27, 2025
EPS Beat/Miss
+6.1%
Price Before
$10.80
Price After
$10.86
Q4 FY2024-0.37%
Report Date
Nov 7, 2024
EPS Beat/Miss
+2.2%
Price Before
$16.06
Price After
$16.00
Q3 FY2024+5.02%
Report Date
Aug 8, 2024
EPS Beat/Miss
-8.3%
Price Before
$21.31
Price After
$22.38
Avg Beat Reaction+2.01%
Avg Miss Reaction+5.02%
Beat Rate7 / 8 quarters
Largest Move+13.58% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NTLA ends December
Intellia Therapeutics, Inc. (NTLA) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.81 — beating the analyst consensus of $-0.92 by +12.0%. NTLA has beaten EPS estimates for 7 consecutive quarters. The next NTLA earnings date is expected around September 1, 2026.
Each quarter, investors track NTLA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NTLA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NTLA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NTLA earnings · 5 questionsIntellia Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. NTLA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NTLA historically reports after market close (AMC).
NTLA earnings datewhen is NTLA earningsNTLA next earnings datewhen does NTLA report earningsNTLA earnings calendar
▸ Source: FMP · Intellia Therapeutics, Inc. SEC filings · US GAAP · Intellia Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026